Interaction of chemokines with their receptors - From initial chemokine binding to receptor activating steps

Current Medicinal Chemistry

Volumn 21, Issue 31, 2014, Pages 3594-3614

  Thiele, Stefanie ^a   Rosenkilde, Mette Marie ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

7TM receptor; Chemokine; G protein coupled receptor (GPCR); Ligand receptor interaction; Mutagenesis; Orthosteric site; Structure; Two step mechanism

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT FACTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; CHEMOKINE; MOLECULAR LIBRARY; PEPTIDE; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; LIGAND BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR LIBRARY; PROTEIN DOMAIN;

CHEMOKINES; HUMANS; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, CHEMOKINE; RECEPTORS, G-PROTEIN-COUPLED; SMALL MOLECULE LIBRARIES;

EID: 84924556075     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140716093155     Document Type: Article

References (261)

1. Viola, A.; Luster, A. D. Chemokines and their receptors: Drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 171-197.
2. Rosenkilde, M. M.; Schwartz, T. W. The chemokine system - a major regulator of angiogenesis in health and disease. APMIS, 2004, 7-8(112), 481-495.
3. Vassilatis, D. K.; Hohmann, J. G.; Zeng, H.; Li, F.; Ranchalis, J. E.; Mortrud, M. T.; Brown, A.; Rodriguez, S. S.; Weller, J. R.; Wright, A. C.; Bergmann, J. E.; Gaitanaris, G. A. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. USA, 2003, 8(100), 4903-4908.
4. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discov., 2006, 12(5), 993-996.
5. Gruber, C. W.; Muttenthaler, M.; Freissmuth, M. Ligand-based peptide design and combinatorial peptide libraries to target G proteincoupled receptors. Curr. Pharm. Des., 2010, 28(16), 3071-3088.
6. Steen, A.; Schwartz, T. W.; Rosenkilde, M. M. Targeting CXCR4 in HIV cell-entry inhibition. Mini Rev. Med. Chem., 2010, 9(14), 1605-1621.
7. Proudfoot, A. E. I.; Power, C. A.; Schwarz, M. K. Anti-chemokine small molecule drugs: A promising future? Expert Opin. Investig. Drugs, 2010, 3(19), 345-355.
8. Scholten, D. J.; Canals, M.; Maussang, D.; Roumen, L.; Smit, M. J.; Wijtmans, M.; De Graaf, C.; Vischer, H. F.; Leurs, R. Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol., 2012, 6(165), 1617-1643.
9. Rosenkilde, M. M. Virus-encoded chemokine receptors-putative novel antiviral drug targets. Neuropharmacology, 2005, 1(48), 1-13.
10. Holst, P. J.; Lüttichau, H. R.; Schwartz, T. W.; Rosenkilde, M. M. Virally encoded chemokines and chemokine receptors in the role of viral infections. Contrib. Microbiol., 2003, 10, 232-252.
11. Murphy, P. M.; Baggiolini, M.; Charo, I. F.; Hébert, C. A.; Horuk, R.; Matsushima, K.; Miller, L. H.; Oppenheim, J. J.; Power, C. A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev., 2000, 1(52), 145-176.
12. Bachelerie, F.; Ben-Baruch, A.; Burkhardt, A. M.; Combadiere, C.; Farber, J. M.; Graham, G. J.; Horuk, R.; Sparre-Ulrich, A. H.; Locati, M.; Luster, A. D.; Mantovani, A.; Matsushima, K.; Murphy, P. M.; Nibbs, R.; Nomiyama, H.; Power, C. A.; Proudfoot, A. E. I.; Rosenkilde, M. M.; Rot, A.; Sozzani, S.; Thelen, M.; Yoshie, O.; Zlotnik, A. International union of pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev., 2014, 1(66), 1-79.
13. Horuk, R. Promiscuous drugs as therapeutics for chemokine receptors. Expert Rev. Mol. Med., 2009, 11, e1.
14. Pease, J. E.; Horuk, R. Small molecule antagonists of chemokine receptors-is promiscuity a virtue? Curr. Top. Med. Chem., 2010, 13(10), 1351-1358.
15. Salanga, C. L.; O'Hayre, M.; Handel, T. Modulation of chemokine receptor activity through dimerization and crosstalk. Cell Mol. Life Sci., 2009, 8(66), 1370-1386.
16. Salanga, C. L.; Handel, T. M. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: The role of structural dynamics in function. Exp. Cell. Res., 2011, 5(317), 590-601.
17. Mortier, A.; Gouwy, M.; Van Damme, J.; Proost, P. Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp. Cell. Res., 2011, 5(317), 642-654.
18. Monteclaro, F. S.; Charo, I. F. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/mip-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem., 1996, 32(271), 19084-19092.
19. Crump, M. P.; Gong, J. H.; Loetscher, P.; Rajarathnam, K.; Amara, A.; Arenzana-Seisdedos, F.; Virelizier, J. L.; Baggiolini, M.; Sykes, B. D.; Clark-Lewis, I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J., 1997, 23(16), 6996-7007.
20. Schwarz, M. K.; Wells, T. N. C. New therapeutics that modulate chemokine networks. Nat. Rev. Drug Discov., 2002, 5(1), 347-358.
21. Yang, J.; Zhang, Y. GPCRSD: a database for experimentally solved GPCR structures. http://zhanglab.ccmb.med.umich.edu/GPCRSD/(Accessed February 20, 2014).
22. Katritch, V.; Cherezov, V.; Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol., 2013, 53, 531-556.
23. Wu, B.; Chien, E. Y. T.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science, 2010, 6007(330), 1066-1071.
24. Park, S. H.; Das, B. B.; Casagrande, F.; Tian, Y.; Nothnagel, H. J.; Chu, M.; Kiefer, H.; Maier, K.; De Angelis, A. A.; Marassi, F. M.; Opella, S. J. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature, 2012, 7426(491), 779-783.
25. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G. W.; Kufareva, I.; Li, T.; Ma, L.; Fenalti, G.; Li, J.; Zhang, W.; Xie, X.; Yang, H.; Jiang, H.; Cherezov, V.; Liu, H.; Stevens, R. C.; Zhao, Q.; Wu, B. Structure of the CCR5 chemokine receptor-hiv entry inhibitor maraviroc complex. Science, 2013, 6152(341), 1387-1390.
26. Rosenkilde, M. M.; Benned-Jensen, T.; Frimurer, T. M.; Schwartz, T. W. The minor binding pocket: A major player in 7TM receptor activation. Trends Pharmacol Sci., 2010, 12(31), 567-574.
27. Benned-Jensen, T.; Rosenkilde, M. M. The role of transmembrane segment II in 7TM receptor activation. Curr. Mol. Pharmacol., 2009, 2(2), 140-148.
28. Schwartz, T. W. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr. Opin. Biotechnol., 1994, 4(5), 434-444.
29. Baldwin, J. M.; Schertler, G. F.; Unger, V. M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of gproteincoupled receptors. J. Mol. Biol., 1997, 1(272), 144-164.
30. Ballesteros, J. A.; Weinstein, H. In: Receptor Molecular Biology; Sealfon, S. C.; Academic Press, 1995, pp. 366-428.
31. Rummel, P. C.; Thiele, S.; Hansen, L. S.; Petersen, T. P.; Sparre-Ulrich, A. H.; Ulven, T.; Rosenkilde, M. M. Extracellular disulfide bridges serve different purposes in two homologous chemokine receptors, CCR1 and CCR5. Mol. Pharmacol., 2013, 84(3), 335-345.
32. Thiele, S.; Malmgaard-Clausen, M.; Engel-Andreasen, J.; Steen, A.; Rummel, P. C.; Nielsen, M. C.; Gloriam, D. E.; Frimurer, T. M.; Ulven, T.; Rosenkilde, M. M. Modulation in selectivity and allosteric properties of small-molecule ligands for cc-chemokine receptors. J. Med. Chem., 2012, 18(55), 8164-8177.
33. Mungalpara, J.; Thiele, S.; Eriksen; Eksteen, J.; Rosenkilde, M. M.; Våbenø, J. Rational design of conformationally constrained cyclopentapeptide antagonists for c-x-c chemokine receptor 4 (CXCR4). J. Med. Chem., 2012, 22(55), 10287-10291.
34. Allen, S. J.; Crown, S. E.; Handel, T. M. Chemokine: Receptor structure, interactions, and antagonism. Annu Rev. Immunol., 2007, 25, 787-820.
35. Keizer, D. W.; Crump, M. P.; Lee, T. W.; Slupsky, C. M.; Clark-Lewis, I.; Sykes, B. D. Human CC chemokine I-309, structural consequences of the additional disulfide bond. Biochemistry, 2000, 20(39), 6053-6059.
36. Sticht, H.; Escher, S. E.; Schweimer, K.; Forssmann, W. G.; Rösch, P.; Adermann, K. Solution structure of the human CC chemokine 2: A monomeric representative of the CC chemokine subtyp. Biochemistry, 1999, 19(38), 5995-6002.
37. Rajarathnam, K.; Li, Y.; Rohrer, T.; Gentz, R. Solution structure and dynamics of myeloid progenitor inhibitory factor-1 (MPIF-1), a novel monomeric CC chemokine. J. Biol. Chem., 2001, 7(276), 4909-4916.
38. Love, M.; Sandberg, J. L.; Ziarek, J. J.; Gerarden, K. P.; Rode, R. R.; Jensen, D. R.; McCaslin, D. R.; Peterson, F. C.; Veldkamp, C. T. Solution structure of CCL21 and identification of a putative CCR7 binding site. Biochemistry, 2012, 3(51), 733-735.
39. Pease, J. E.; Wang, J.; Ponath, P. D.; Murphy, P. M. The n-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for mip-1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation. J. Biol. Chem., 1998, 32(273), 19972-19976.
40. Wells, T. N. C.; Proudfoot, A. E. I.; Power, C. A.; Lusti-Narasimhan, M.; Alouani, S.; Hoogewerf, A. J.; Peitsch, M. C. The molecular basis of the chemokine/chemokine receptor interaction-scope for design of chemokine antagonists. Methods, 1996, 1(10), 126-134.
41. Suetomi, K.; Rojo, D.; Navarro, J. Identification of a signal transduction switch in the chemokine receptor CXCR1. J. Biol. Chem., 2002, 35(277), 31563-31566.
42. Colvin, R. A.; Campanella, G. S. V.; Manice, L. A.; Luster, A. D. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol. Cell. Biol., 2006, 15(26), 5838-5849.
43. Monteclaro, F. S.; Charo, I. F. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudotethered ligand. J. Biol. Chem., 1997, 37(272), 23186-23190.
44. Samson, M.; La Rosa, G.; Libert, F.; Paindavoine, P.; Detheux, M.; Vassart, G.; Parmentier, M. The second extracellular loop of CCR5 is the major determinant of ligand specificity. J. Biol. Chem., 1997, 40(272), 24934-24941.
45. Hemmerich, S.; Paavola, C.; Bloom, A.; Bhakta, S.; Freedman, R.; Grunberger, D.; Krstenansky, J.; Lee, S.; McCarley, D.; Mulkins, M.; Wong, B.; Pease, J.; Mizoue, L.; Mirzadegan, T.; Polsky, I.; Thompson, K.; Handel, T. M.; Jarnagin, K. Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. Biochemistry, 1999, 40(38), 13013-13025.
46. Preobrazhensky, A. A.; Dragan, S.; Kawano, T.; Gavrilin, M. A.; Gulina, I. V.; Chakravarty, L.; Kolattukudy, P. E. Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular n-terminal region. J. Immunol., 2000, 9(165), 5295-5303.
47. Mirzadegan, T.; Diehl, F.; Ebi, B.; Bhakta, S.; Polsky, I.; McCarley, D.; Mulkins, M.; Weatherhead, G. S.; Lapierre, J. M.; Dankwardt, J.; Morgans, D.; Wilhelm, R.; Jarnagin, K. Identification of the binding site for a novel class of ccr2b chemokine receptor antagonists: Binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem., 2000, 33(275), 25562-25571.
48. Gavrilin, M. A.; Gulina, I. V.; Kawano, T.; Dragan, S.; Chakravarti, L.; Kolattukudy, P. E. Site-directed mutagenesis of CCR2 identified amino acid residues in transmembrane helices 1, 2, and 7 important for MCP-1 binding and biological functions. Biochem. Biophys. Res. Commun., 2005, 2(327), 533-540.
49. Thiele, S.; Steen, A.; Jensen, P. C.; Mokrosinski, J.; Frimurer, T. M.; Rosenkilde, M. M. Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J. Biol. Chem., 2011, 43(286), 37543-37554.
50. Han, K. H.; Green, S. R.; Tangirala, R. K.; Tanaka, S.; Quehenberger, O. Role of the first extracellular loop in the functional activation of CCR2. The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signaling. J. Biol. Chem., 1999, 45(274), 32055-32062.
51. Jarnagin, K.; Grunberger, D.; Mulkins, M.; Wong, B.; Hemmerich, S.; Paavola, C.; Bloom, A.; Bhakta, S.; Diehl, F.; Freedman, R.; McCarley, D.; Polsky, I.; Ping-Tsou, A.; Kosaka, A.; Handel, T. M. Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2. Biochemistry, 1999, 49(38), 16167-16177.
52. Beck, C. G.; Studer, C.; Zuber, J. F.; Demange, B. J.; Manning, U.; Urfer, R. The viral CC chemokine-binding protein vcci inhibits monocyte chemoattractant protein-1 activity by masking its ccr2bbinding site. J. Biol. Chem., 2001, 46(276), 43270-43276.
53. Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISSMODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics, 2006, 2(22), 195-201.
54. Bordoli, L.; Kiefer, F.; Arnold, K.; Benkert, P.; Battey, J.; Schwede, T. Protein structure homology modeling using SWISSMODEL workspace. Nat. Protoc., 2009, 1(4), 1-13.
55. La Rosa, G. J.; Thomas, K. M.; Kaufmann, M. E.; Mark, R.; White, M.; Taylor, L.; Gray, G.; Witt, D.; Navarro, J. Amino terminus of the interleukin-8 receptor is a major determinant of receptor subtype specificity. J. Biol. Chem., 1992, 35(267), 25402-25406.
56. Suzuki, H.; Prado, G. N.; Wilkinson, N.; Navarro, J. The N terminus of interleukin-8 (IL-8) receptor confers high affinity binding to human IL-8. J. Biol. Chem., 1994, 28(269), 18263-18266.
57. Wu, L.; Ruffing, N.; Shi, X.; Newman, W.; Soler, D.; Mackay, C. R.; Qin, S. Discrete steps in binding and signaling of interleukin-8 with its receptor. J. Biol. Chem., 1996, 49(271), 31202-31209.
58. Rajagopalan, L.; Rajarathnam, K. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of n-terminal domain. J. Biol. Chem., 2004, 29(279), 30000-30008.
59. Fernando, H.; Nagle, G. T.; Rajarathnam, K. Thermodynamic characterization of interleukin-8 monomer binding to CXCR1 receptor n-terminal domain. FEBS J., 2007, 1(274), 241-251.
60. Hébert, C. A.; Chuntharapai, A.; Smith, M.; Colby, T.; Kim, J.; Horuk, R. Partial functional mapping of the human interleukin-8 type A receptor. Identification of a major ligand binding domain. J. Biol. Chem., 1993, 25(268), 18549-18553.
61. Clubb, R. T.; Omichinski, J. G.; Clore, G. M.; Gronenborn, A. M. Mapping the binding surface of interleukin-8 complexed with an nterminal fragment of the type 1 human interleukin-8 receptor. FEBS Lett., 1994, 1(338), 93-97.
62. Leong, S. R.; Kabakoff, R. C.; Hébert, C. A. Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction. J. Biol. Chem., 1994, 30(269), 19343-19348.
63. Skelton, N. J.; Quan, C.; Reilly, D.; Lowman, H. Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. Structure, 1999, 2(7), 157-168.
64. Schraufstätter, I. U.; Ma, M.; Oades, Z. G.; Barritt, D. S.; Cochrane, C. G. The role of tyr13 and lys15 of interleukin-8 in the high affinity interaction with the interleukin-8 receptor type A. J. Biol. Chem., 1995, 18(270), 10428-10431.
65. Bertini, R.; Allegretti, M.; Bizzarri, C.; Moriconi, A.; Locati, M.; Zampella, G.; Cervellera, M. N.; Di Cioccio, V.; Cesta, M. C.; Galliera, E.; Martinez, F. O.; Di Bitondo, R.; Troiani, G.; Sabbatini, V.; D'Anniballe, G.; Anacardio, R.; Cutrin, J. C.; Cavalieri, B.; Mainiero, F.; Strippoli, R.; Villa, P.; Di Girolamo, M.; Martin, F.; Gentile, M.; Santoni, A.; Corda, D.; Poli, G.; Mantovani, A.; Ghezzi, P.; Colotta, F. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA, 2004, 32(101), 11791-11796.
66. Bertini, R.; Barcelos, L. S.; Beccari, A. R.; Cavalieri, B.; Moriconi, A.; Bizzarri, C.; Di Benedetto, P.; Di Giacinto, C.; Gloaguen, I.; Galliera, E.; Corsi, M. M.; Russo, R. C.; Andrade, S. P.; Cesta, M. C.; Nano, G.; Aramini, A.; Cutrin, J. C.; Locati, M.; Allegretti, M.; Teixeira, M. M. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 noncompetitive allosteric inhibitor. Br. J. Pharmacol., 2012, 2(165), 436-454.
67. Lowman, H. B.; Slagle, P. H.; De Forge, L. E.; Wirth, C. M.; Gillece-Castro, B. L.; Bourell, J. H.; Fairbrother, W. J. Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities. J. Biol. Chem., 1996, 24(271), 14344-14352.
68. Williams, G.; Borkakoti, N.; Bottomley, G. A.; Cowan, I.; Fallowfield, A. G.; Jones, P. S.; Kirtland, S. J.; Price, G. J.; Price, L. Mutagenesis studies of interleukin-8. Identification of a second epitope involved in receptor binding. J. Biol. Chem., 1996, 16(271), 9579-9586.
69. Hammond, M. E.; Shyamala, V.; Siani, M. A.; Gallegos, C. A.; Feucht, P. H.; Abbott, J.; Lapointe, G. R.; Moghadam, M.; Khoja, H.; Zakel, J.; Tekamp-Olson, P. Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surfaceaccessible hydrophobic pocket. J. Biol. Chem., 1996, 14(271), 8228-8235.
70. Suetomi, K.; Lu, Z.; Heck, T.; Wood, T. G.; Prusak, D. J.; Dunn, K. J.; Navarro, J. Differential mechanisms of recognition and activation of interleukin-8 receptor subtypes. J. Biol. Chem., 1999, 17(274), 11768-11772.
71. Clark-Lewis, I.; Schumacher, C.; Baggiolini, M.; Moser, B. Structureactivity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of nh2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J. Biol. Chem., 1991, 34(266), 23128-23134.
72. Hébert, C. A.; Vitangcol, R. V.; Baker, J. B. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J. Biol. Chem., 1991, 28(266), 18989-18994.
73. Moser, B.; Dewald, B.; Barella, L.; Schumacher, C.; Baggiolini, M.; Clark-Lewis, I. Interleukin-8 antagonists generated by nterminal modification. J. Biol. Chem., 1993, 10(268), 7125-7128.
74. Jones, S. A.; Dewald, B.; Clark-Lewis, I.; Baggiolini, M. Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J. Biol. Chem., 1997, 26(272), 16166-16169.
75. Petit, S. J.; Chayen, N. E.; Pease, J. E. Site-directed mutagenesis of the chemokine receptor CXCR6 suggests a novel paradigm for interactions with the ligand CXCL16. Eur. J. Immunol., 2008, 8(38), 2337-2350.
76. Fong, A. M.; Alam, S. M.; Imai, T.; Haribabu, B.; Patel, D. D. CX3CR1 tyrosine sulfation enhances fractalkine-induced cell adhesion. J. Biol. Chem., 2002, 22(277), 19418-19423.
77. Ziarek, J. J.; Getschman, A. E.; Butler, S. J.; Taleski, D.; Stephens, B.; Kufareva, I.; Handel, T. M.; Payne, R. J.; Volkman, B. F. Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomerspecific contacts and chemokine allostery. ACS Chem. Biol., 2013, 9(8), 1955-1963.
78. Veldkamp, C. T.; Seibert, C.; Peterson, F. C.; Sakmar, T. P.; Volkman, B. F. Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived factor-1alpha (sdf-1alpha/CXCL12). J. Mol. Biol., 2006, 5(359), 1400-1409.
79. Veldkamp, C. T.; Seibert, C.; Peterson, F. C.; De La Cruz, N. B.; Haugner, J. C.; Basnet, H.; Sakmar, T. P.; Volkman, B. F. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci. Signal., 2008, 37(1), ra4.
80. Seibert, C.; Veldkamp, C. T.; Peterson, F. C.; Chait, B. T.; Volkman, B. F.; Sakmar, T. P. Sequential tyrosine sulfation of CXCR4 by tyrosylprotein sulfotransferases. Biochemistry, 2008, 43(47), 11251-11262.
81. Gao, J.-M.; Xiang, R.-L.; Jiang, L.; Li, W.-H.; Feng, Q.-P.; Guo, Z.-J.; Sun, Q.; Zeng, Z.-P.; Fang, F.-D. Sulfated tyrosines 27 and 29 in the n-terminus of human CXCR3 participate in binding native IP-10. Acta Pharmacol. Sin., 2009, 2(30), 193-201.
82. Farzan, M.; Mirzabekov, T.; Kolchinsky, P.; Wyatt, R.; Cayabyab, M.; Gerard, N. P.; Gerard, C.; Sodroski, J.; Choe, H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell, 1999, 5(96), 667-676.
83. Seibert, C.; Cadene, M.; Sanfiz, A.; Chait, B. T.; Sakmar, T. P. Tyrosine sulfation of CCR5 n-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence. Proc. Natl. Acad. Sci. USA, 2002, 17(99), 11031-11036.
84. Ludeman, J. P.; Stone, M. J. The structural role of receptor tyrosine sulfation in chemokine recognition. Br. J. Pharmacol., 2013, 171, 1167-1179
85. Rosenkilde, M. M.; Schwartz, T. W. GluVII:06-a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr. Top. Med. Chem., 2006, 13(6), 1319-1333.
86. Jensen, P. C.; Rosenkilde, M. M. Chapter 8. Activation mechanisms of chemokine receptors. Methods Enzymol., 2009, 461, 171-190.
87. Wells, T. N. C.; Power, C. A.; Shaw, J. P.; Proudfoot, A. E. I. Chemokine blockers-therapeutics in the making? Trends Pharmacol. Sci., 2006, 1(27), 41-47.
88. Proudfoot, A. E. I.; Power, C. A.; Rommel, C.; Wells, T. N. C. Strategies for chemokine antagonists as therapeutics. Semin. Immunol., 2003, 1(15), 57-65.
89. Jensen, P. C.; Thiele, S.; Ulven, T.; Schwartz, T. W.; Rosenkilde, M. M. Positive versus negative modulation of different endogenous chemokines for cc-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding. J. Biol. Chem., 2008, 34(283), 23121-23128.
90. Kenakin, T. G protein coupled receptors as allosteric proteins and the role of allosteric modulators. J. Recept. Signal Transduct. Res., 2010, 5(30), 313-321.
91. Jensen, P. C.; Thiele, S.; Steen, A.; Elder, A.; Kolbeck, R.; Ghosh, S.; Frimurer, T. M.; Rosenkilde, M. M. Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2. Br. J. Pharmacol., 2012, 1(166), 258-275.
92. Zoffmann, S.; Turcatti, G.; Galzi, J.; Dahl, M.; Chollet, A. Synthesis and characterization of fluorescent and photoactivatable mip-1alpha ligands and interactions with chemokine receptors CCR1 and CCR5. J. Med. Chem., 2001, 2(44), 215-222.
93. Zoffmann, S.; Chollet, A.; Galzi, J.-L. Identification of the extracellular loop 2 as the point of interaction between the N terminus of the chemokine mip-1alpha and its CCR1 receptor. Mol. Pharmacol., 2002, 3(62), 729-736.
94. De Mendonça, F. L.; Da Fonseca, P. C. A.; Phillips, R. M.; Saldanha, J. W.; Williams, T. J.; Pease, J. E. Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J. Biol. Chem., 2005, 6(280), 4808-4816.
95. Blanpain, C.; Doranz, B. J.; Vakili, J.; Rucker, J.; Govaerts, C.; Baik, S. S.; Lorthioir, O.; Migeotte, I.; Libert, F.; Baleux, F.; Vassart, G.; Doms, R. W.; Parmentier, M. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 env protein. J. Biol. Chem., 1999, 49(274), 34719-34727.
96. Farzan, M.; Choe, H.; Vaca, L.; Martin, K.; Sun, Y.; Desjardins, E.; Ruffing, N.; Wu, L.; Wyatt, R.; Gerard, N.; Gerard, C.; Sodroski, J. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol., 1998, 2(72), 1160-1164.
97. Dragic, T.; Trkola, A.; Lin, S. W.; Nagashima, K. A.; Kajumo, F.; Zhao, L.; Olson, W. C.; Wu, L.; Mackay, C. R.; Allaway, G. P.; Sakmar, T. P.; Moore, J. P.; Maddon, P. J. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol., 1998, 1(72), 279-285.
98. Zhou, N.; Luo, Z.; Hall, J. W.; Luo, J.; Han, X.; Huang, Z. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction. Eur. J. Immunol., 2000, 1(30), 164-173.
99. Seibert, C.; Ying, W.; Gavrilov, S.; Tsamis, F.; Kuhmann, S. E.; Palani, A.; Tagat, J. R.; Clader, J. W.; McCombie, S. W.; Baroudy, B. M.; Smith, S. O.; Dragic, T.; Moore, J. P.; Sakmar, T. P. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology, 2006, 1(349), 41-54.
100. Maeda, K.; Das, D.; Ogata-Aoki, H.; Nakata, H.; Miyakawa, T.; Tojo, Y.; Norman, R.; Takaoka, Y.; Ding, J.; Arnold, G. F.; Arnold, E.; Mitsuya, H. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem., 2006, 18(281), 12688-12698.
101. Blanpain, C.; Lee, B.; Vakili, J.; Doranz, B. J.; Govaerts, C.; Migeotte, I.; Sharron, M.; Dupriez, V.; Vassart, G.; Doms, R. W.; Parmentier, M. Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J. Biol. Chem., 1999, 27(274), 18902-18908.
102. Wu, L.; La Rosa, G.; Kassam, N.; Gordon, C. J.; Heath, H.; Ruffing, N.; Chen, H.; Humblias, J.; Samson, M.; Parmentier, M.; Moore, J. P.; Mackay, C. R. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med., 1997, 8(186), 1373-1381.
103. Lee, B.; Sharron, M.; Blanpain, C.; Doranz, B. J.; Vakili, J.; Setoh, P.; Berg, E.; Liu, G.; Guy, H. R.; Durell, S. R.; Parmentier, M.; Chang, C. N.; Price, K.; Tsang, M.; Doms, R. W. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem., 1999, 14(274), 9617-9626.
104. Efremov, R. G.; Legret, F.; Vergoten, G.; Capron, A.; Bahr, G. M.; Arseniev, A. S. Molecular modeling of HIV-1 coreceptor CCR5 and exploring of conformational space of its extracellular domain in molecular dynamics simulation. J. Biomol. Struct. Dyn., 1998, 1(16), 77-90.
105. Blanpain, C.; Doranz, B. J.; Bondue, A.; Govaerts, C.; De Leener, A.; Vassart, G.; Doms, R. W.; Proudfoot, A.; Parmentier, M. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem., 2003, 7(278), 5179-5187.
106. Govaerts, C.; Bondue, A.; Springael, J.-Y.; Olivella, M.; Deupi, X.; Le Poul, E.; Wodak, S. J.; Parmentier, M.; Pardo, L.; Blanpain, C. Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J. Biol. Chem., 2003, 3(278), 1892-1903.
107. Govaerts, C.; Blanpain, C.; Deupi, X.; Ballet, S.; Ballesteros, J. A.; Wodak, S. J.; Vassart, G.; Pardo, L.; Parmentier, M. The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J. Biol. Chem., 2001, 16(276), 13217-13225.
108. Blanpain, C.; Buser, R.; Power, C. A.; Edgerton, M.; Buchanan, C.; Mack, M.; Simmons, G.; Clapham, P. R.; Parmentier, M.; Proudfoot, A. E. A chimeric mip-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors. J. Leukoc. Biol., 2001, 6(69), 977-985.
109. Sabroe, I.; Peck, M. J.; Van Keulen, B. J.; Jorritsma, A.; Simmons, G.; Clapham, P. R.; Williams, T. J.; Pease, J. E. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and ccr3-mediated HIV-1 entry. J. Biol. Chem., 2000, 34(275), 25985-25992.
110. Berkhout, T. A.; Blaney, F. E.; Bridges, A. M.; Cooper, D. G.; Forbes, I. T.; Gribble, A. D.; Groot, P. H. E.; Hardy, A.; Ife, R. J.; Kaur, R.; Moores, K. E.; Shillito, H.; Willetts, J.; Witherington, J. CCR2: Characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J. Med. Chem., 2003, 19(46), 4070-4086.
111. Hall, S. E.; Mao, A.; Nicolaidou, V.; Finelli, M.; Wise, E. L.; Nedjai, B.; Kanjanapangka, J.; Harirchian, P.; Chen, D.; Selchau, V.; Ribeiro, S.; Schyler, S.; Pease, J. E.; Horuk, R.; Vaidehi, N. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol. Pharmacol., 2009, 6(75), 1325-1336.
112. Kristiansen, K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of g-protein-coupled receptors: Molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther., 2004, 1(103), 21-80.
113. Schwartz, T. W.; Rosenkilde, M. M. Is there a 'lock' for all agonist 'keys' in 7TM receptors? Trends Pharmacol. Sci., 1996, 6(17), 213-216.
114. Siciliano, S. J.; Rollins, T. E.; De Martino, J.; Konteatis, Z.; Malkowitz, L.; Van Riper, G.; Bondy, S.; Rosen, H.; Springer, M. S. Twosite binding of c5a by its receptor: An alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA, 1994, 4(91), 1214-1218.
115. Klos, A.; Wende, E.; Wareham, K. J.; Monk, P. N. International union of pharmacology. LXXXVII. Complement peptide c5a, c4a, and c3a receptors. Pharmacol. Rev., 2013, 1(65), 500-543.
116. Unson, C. G. Molecular determinants of glucagon receptor signaling. Biopolymers, 2002, 4(66), 218-235.
117. Vilardaga, J.-P.; Romero, G.; Friedman, P. A.; Gardella, T. J. Molecular basis of parathyroid hormone receptor signaling and trafficking: A family B GPCR paradigm. Cell. Mol. Life Sci., 2011, 1(68), 1-13.
118. Ames, R. S.; Tornetta, M. A.; Foley, J. J.; Hugli, T. E.; Sarau, H. M. Evidence that the receptor for c4a is distinct from the c3a receptor. Immunopharmacology, 1997, 1-2(38), 87-92.
119. Lienenklaus, S.; Ames, R. S.; Tornetta, M. A.; Sarau, H. M.; Foley, J. J.; Crass, T.; Sohns, B.; Raffetseder, U.; Grove, M.; Hölzer, A.; Klos, A.; Köhl, J.; Bautsch, W. Human anaphylatoxin c4a is a potent agonist of the guinea pig but not the human c3a receptor. J. Immunol., 1998, 5(161), 2089-2093.
120. Oppermann, M.; Raedt, U.; Hebell, T.; Schmidt, B.; Zimmermann, B.; Götze, O. Probing the human receptor for c5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the nh2-terminal domain. J. Immunol., 1993, 7(151), 3785-3794.
121. De Martino, J. A.; Van Riper, G.; Siciliano, S. J.; Molineaux, C. J.; Konteatis, Z. D.; Rosen, H.; Springer, M. S. The amino terminus of the human c5a receptor is required for high affinity c5a binding and for receptor activation by c5a but not c5a analogs. J. Biol. Chem., 1994, 20(269), 14446-14450.
122. Chao, T. H.; Ember, J. A.; Wang, M.; Bayon, Y.; Hugli, T. E.; Ye, R. D. Role of the second extracellular loop of human c3a receptor in agonist binding and receptor function. J. Biol. Chem., 1999, 14(274), 9721-9728.
123. Crass, T.; Ames, R. S.; Sarau, H. M.; Tornetta, M. A.; Foley, J. J.; Köhl, J.; Klos, A.; Bautsch, W. Chimeric receptors of the human c3a receptor and c5a receptor (CD88). J. Biol. Chem., 1999, 13(274), 8367-8370.
124. Mollison, K. W.; Mandecki, W.; Zuiderweg, E. R.; Fayer, L.; Fey, T. A.; Krause, R. A.; Conway, R. G.; Miller, L.; Edalji, R. P.; Shallcross, M. A. Identification of receptor-binding residues in the inflammatory complement protein c5a by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA, 1989, 1(86), 292-296.
125. Chen, Z.; Zhang, X.; Gonnella, N. C.; Pellas, T. C.; Boyar, W. C.; Ni, F. Residues 21-30 within the extracellular n-terminal region of the c5a receptor represent a binding domain for the c5a anaphylatoxin. J. Biol. Chem., 1998, 17(273), 10411-10419.
126. Farzan, M.; Schnitzler, C. E.; Vasilieva, N.; Leung, D.; Kuhn, J.; Gerard, C.; Gerard, N. P.; Choe, H. Sulfated tyrosines contribute to the formation of the c5a docking site of the human c5a anaphylatoxin receptor. J. Exp. Med., 2001, 9(193), 1059-1066.
127. Gao, J.; Choe, H.; Bota, D.; Wright, P. L.; Gerard, C.; Gerard, N. P. Sulfation of tyrosine 174 in the human c3a receptor is essential for binding of c3a anaphylatoxin. J. Biol. Chem., 2003, 39(278), 37902-37908.
128. Huber-Lang, M. S.; Sarma, J. V.; McGuire, S. R.; Lu, K. T.; Padgaonkar, V. A.; Younkin, E. M.; Guo, R. F.; Weber, C. H.; Zuiderweg, E. R.; Zetoune, F. S.; Ward, P. A. Structure-function relationships of human c5a and c5ar. J. Immunol., 2003, 12(170), 6115-6124.
129. Hagemann, I. S.; Narzinski, K. D.; Floyd, D. H.; Baranski, T. J. Random mutagenesis of the complement factor 5a (c5a) receptor N terminus provides a structural constraint for c5a docking. J. Biol. Chem., 2006, 48(281), 36783-36792.
130. Hagemann, I. S.; Miller, D. L.; Klco, J. M.; Nikiforovich, G. V.; Baranski, T. J. Structure of the complement factor 5a receptorligand complex studied by disulfide trapping and molecular modeling. J. Biol. Chem., 2008, 12(283), 7763-7775.
131. Pease, J. E.; Burton, D. R.; Barker, M. D. Generation of chimeric c5a/formyl peptide receptors: Towards the identification of the human c5a receptor binding site. Eur. J. Immunol., 1994, 1(24), 211-215.
132. De Martino, J. A.; Konteatis, Z. D.; Siciliano, S. J.; Van Riper, G.; Underwood, D. J.; Fischer, P. A.; Springer, M. S. Arginine 206 of the c5a receptor is critical for ligand recognition and receptor activation by c-terminal hexapeptide analogs. J. Biol. Chem., 1995, 27(270), 15966-15969.
133. Sun, J.; Ember, J. A.; Chao, T. H.; Fukuoka, Y.; Ye, R. D.; Hugli, T. E. Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled c3a receptor. Protein Sci., 1999, 11(8), 2304-2311.
134. Gerber, B. O.; Meng, E. C.; Dotsch, V.; Baranski, T. J.; Bourne, H. R. An activation switch in the ligand binding pocket of the c5a receptor. J. Biol. Chem., 2001, 5(276), 3394-3400.
135. Higginbottom, A.; Cain, S. A.; Woodruff, T. M.; Proctor, L. M.; Madala, P. K.; Tyndall, J. D. A.; Taylor, S. M.; Fairlie, D. P.; Monk, P. N. Comparative agonist/antagonist responses in mutant human c5a receptors define the ligand binding site. J. Biol. Chem., 2005, 18(280), 17831-17840.
136. Nikiforovich, G. V.; Marshall, G. R.; Baranski, T. J. Modeling molecular mechanisms of binding of the anaphylatoxin c5a to the c5a receptor. Biochemistry, 2008, 10(47), 3117-3130.
137. Kawai, M.; Quincy, D. A.; Lane, B.; Mollison, K. W.; Luly, J. R.; Carter, G. W. Identification and synthesis of a receptor binding site of human anaphylatoxin c5a. J. Med. Chem., 1991, 7(34), 2068-2071.
138. Ember, J. A.; Sanderson, S. D.; Taylor, S. M.; Kawahara, M.; Hugli, T. E. Biologic activity of synthetic analogues of c5a anaphylatoxin. J. Immunol., 1992, 10(148), 3165-3173.
139. Bautsch, W.; Kretzschmar, T.; Stühmer, T.; Kola, A.; Emde, M.; Köhl, J.; Klos, A.; Bitter-Suermann, D. A recombinant hybrid anaphylatoxin with dual c3a/c5a activity. Biochem. J., 1992, 288(Pt 1), 261-266.
140. Zhang, X.; Boyar, W.; Galakatos, N.; Gonnella, N. C. Solution structure of a unique c5a semi-synthetic antagonist: Implications in receptor binding. Protein Sci., 1997, 1(6), 65-72.
141. Hjorth, S. A.; Schwartz, T. W. Glucagon and GLP-1 receptors: Lessons from chimeric ligands and receptors. Acta Physiol. Scand., 1996, 3(157), 343-345.
142. Gardella, T. J.; Jüppner, H. Molecular properties of the PTH/pthrp receptor. Trends Endocrinol. Metab., 2001, 5(12), 210-217.
143. Castro, M.; Nikolaev, V. O.; Palm, D.; Lohse, M. J.; Vilardaga, J.-P. Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc. Natl. Acad. Sci. USA, 2005, 44(102), 16084-16089.
144. Krstenansky, J. L.; Trivedi, D.; Hruby, V. J. Importance of the 10-13 region of glucagon for its receptor interactions and activation of adenylate cyclase. Biochemistry, 1986, 13(25), 3833-3839.
145. Unson, C. G.; Andreu, D.; Gurzenda, E. M.; Merrifield, R. B. Synthetic peptide antagonists of glucagon. Proc. Natl. Acad. Sci. USA, 1987, 12(84), 4083-4087.
146. Unson, C. G.; Macdonald, D.; Ray, K.; Durrah, T. L.; Merrifield, R. B. Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. J. Biol. Chem., 1991, 5(266), 2763-2766.
147. Unson, C. G.; Wu, C. R.; Merrifield, R. B. Roles of aspartic acid 15 and 21 in glucagon action: Receptor anchor and surrogates for aspartic acid 9. Biochemistry, 1994, 22(33), 6884-6887.
148. Vilardaga, J. P.; Di Paolo, E.; Bialek, C.; De Neef, P.; Waelbroeck, M.; Bollen, A.; Robberecht, P. Mutational analysis of extracellular cysteine residues of rat secretin receptor shows that disulfide bridges are essential for receptor function. Eur. J. Biochem., 1997, 1(246), 173-180.
149. Unson, C. G.; Wu, C. R.; Cheung, C. P.; Merrifield, R. B. Positively charged residues at positions 12, 17, and 18 of glucagon ensure maximum biological potency. J. Biol. Chem., 1998, 17(273), 10308-10312.
150. Mannstadt, M.; Luck, M. D.; Gardella, T. J.; Jüppner, H. Evidence for a ligand interaction site at the amino-terminus of the parathyroid hormone (PTH)/pth-related protein receptor from cross-linking and mutational studies. J. Biol. Chem., 1998, 27(273), 16890-16896.
151. Asmann, Y. W.; Dong, M.; Ganguli, S.; Hadac, E. M.; Miller, L. J. Structural insights into the amino-terminus of the secretin receptor: I. Status of cysteine and cystine residues. Mol. Pharmacol., 2000, 5(58), 911-919.
152. Grauschopf, U.; Lilie, H.; Honold, K.; Wozny, M.; Reusch, D.; Esswein, A.; Schäfer, W.; Rücknagel, K. P.; Rudolph, R. The nterminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. Biochemistry, 2000, 30(39), 8878-8887.
153. Perrin, M. H.; Fischer, W. H.; Kunitake, K. S.; Craig, A. G.; Koerber, S. C.; Cervini, L. A.; Rivier, J. E.; Groppe, J. C.; Greenwald, J.; Møller Nielsen, S.; Vale, W. W. Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor. J. Biol. Chem., 2001, 34(276), 31528-31534.
154. Bazarsuren, A.; Grauschopf, U.; Wozny, M.; Reusch, D.; Hoffmann, E.; Schaefer, W.; Panzner, S.; Rudolph, R. In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. Biophys. Chem., 2002, 2-3(96), 305-318.
155. Buggy, J. J.; Livingston, J. N.; Rabin, D. U.; Yoo-Warren, H. Glucagon. Glucagon-like peptide I receptor chimeras reveal domains that determine specificity of glucagon binding. J. Biol. Chem., 1995, 13(270), 7474-7478.
156. Cao, Y. J.; Gimpl, G.; Fahrenholz, F. The amino-terminal fragment of the adenylate cyclase activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain. Biochem. Biophys. Res. Commun., 1995, 2(212), 673-680.
157. Gourlet, P.; Vilardaga, J. P.; De Neef, P.; Waelbroeck, M.; Vandermeers, A.; Robberecht, P. The c-terminus ends of secretin and VIP interact with the n-terminal domains of their receptors. Peptides, 1996, 5(17), 825-829.
158. Dror, R. O.; Pan, A. C.; Arlow, D. H.; Borhani, D. W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D. E. Pathway and mechanism of drug binding to g-protein-coupled receptors. Proc. Natl. Acad. Sci. USA, 2011, 32(108), 13118-13123.
159. Handel, T. M.; Domaille, P. J. Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry, 1996, 21(35), 6569-6584.
160. Lubkowski, J.; Bujacz, G.; Boqué, L.; Domaille, P. J.; Handel, T. M.; Wlodawer, A. The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat. Struct. Biol., 1997, 1(4), 64-69.
161. Czaplewski, L. G.; McKeating, J.; Craven, C. J.; Higgins, L. D.; Appay, V.; Brown, A.; Dudgeon, T.; Howard, L. A.; Meyers, T.; Owen, J.; Palan, S. R.; Tan, P.; Wilson, G.; Woods, N. R.; Heyworth, C. M.; Lord, B. I.; Brotherton, D.; Christison, R.; Craig, S.; Cribbes, S.; Edwards, R. M.; Evans, S. J.; Gilbert, R.; Morgan, P.; Randle, E.; Schofield, N.; Varley, P. G.; Fisher, J.; Waltho, J. P.; Hunter, M. G. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, mip-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J. Biol. Chem., 1999, 23(274), 16077-16084.
162. Ren, M.; Guo, Q.; Guo, L.; Lenz, M.; Qian, F.; Koenen, R. R.; Xu, H.; Schilling, A. B.; Weber, C.; Ye, R. D.; Dinner, A. R.; Tang, W.-J. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J., 2010, 23(29), 3952-3966.
163. Skelton, N. J.; Aspiras, F.; Ogez, J.; Schall, T. J. Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry, 1995, 16(34), 5329-5342.
164. Chung, C. W.; Cooke, R. M.; Proudfoot, A. E.; Wells, T. N. The three-dimensional solution structure of RANTES. Biochemistry, 1995, 29(34), 9307-9314.
165. Wang, X.; Watson, C.; Sharp, J. S.; Handel, T. M.; Prestegard, J. H. Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data. Structure, 2011, 8(19), 1138-1148.
166. Kim, K. S.; Rajarathnam, K.; Clark-Lewis, I.; Sykes, B. D. Structural characterization of a monomeric chemokine: Monocyte chemoattractant protein-3. FEBS Lett., 1996, 2-3(395), 277-282.
167. Meunier, S.; Bernassau, J. M.; Guillemot, J. C.; Ferrara, P.; Darbon, H. Determination of the three-dimensional structure of CC chemokine monocyte chemoattractant protein 3 by 1H two-dimensional NMR spectroscopy. Biochemistry, 1997, 15(36), 4412-4422.
168. Blaszczyk, J.; Coillie, E. V.; Proost, P.; Damme, J. V.; Opdenakker, G.; Bujacz, G. D.; Wang, J. M.; Ji, X. Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochemistry, 2000, 46(39), 14075-14081.
169. Crump, M. P.; Rajarathnam, K.; Kim, K. S.; Clark-Lewis, I.; Sykes, B. D. Solution structure of eotaxin, a chemokine that selectively recruits eosinophils in allergic inflammation. J. Biol. Chem., 1998, 35(273), 22471-22479.
170. Barinka, C.; Prahl, A.; Lubkowski, J. Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr. D. Biol. Crystallogr., 2008, Pt. 3(64), 273-278.
171. Blain, K. Y.; Kwiatkowski, W.; Zhao, Q.; La Fleur, D.; Naik, C.; Chun, T.-W.; Tsareva, T.; Kanakaraj, P.; Laird, M. W.; Shah, R.; George, L.; Sanyal, I.; Moore, P. A.; Demeler, B.; Choe, S. Struc tural and functional characterization of CC chemokine CCL14. Biochemistry, 2007, 35(46), 10008-10015.
172. Asojo, O. A.; Boulègue, C.; Hoover, D. M.; Lu, W.; Lubkowski, J. Structures of thymus and activation-regulated chemokine (TARC). Acta Crystallogr. D. Biol. Crystallogr., 2003, Pt. 7(59), 1165-1173.
173. Islam, S. A.; Ling, M. F.; Leung, J.; Shreffler, W. G.; Luster, A. D. Identification of human CCR8 as a CCL18 receptor. J. Exp. Med., 2013, 10(210), 1889-1898.
174. Hoover, D. M.; Boulegue, C.; Yang, D.; Oppenheim, J. J.; Tucker, K.; Lu, W.; Lubkowski, J. The structure of human macrophage inflammatory protein-3alpha/CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human betadefensins. J. Biol. Chem., 2002, 40(277), 37647-37654.
175. Malik, Z. A.; Tack, B. F. Structure of human mip-3alpha chemokine. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun., 2006, Pt 7(62), 631-634.
176. Chan, D. I.; Hunter, H. N.; Tack, B. F.; Vogel, H. J. Human macrophage inflammatory protein 3alpha: Protein and peptide nuclear magnetic resonance solution structures, dimerization, dynamics, and anti-infective properties. Antimicrob. Agents Chemother., 2008, 3(52), 883-894.
177. Mayer, K. L.; Stone, M. J. NMR solution structure and receptor peptide binding of the CC chemokine eotaxin-2. Biochemistry, 2000, 29(39), 8382-8395.
178. Ye, J.; Mayer, K. L.; Mayer, M. R.; Stone, M. J. NMR solution structure and backbone dynamics of the CC chemokine eotaxin-3. Biochemistry, 2001, 26(40), 7820-7831.
179. Jansma, A. L.; Kirkpatrick, J. P.; Hsu, A. R.; Handel, T. M.; Nietlispach, D. NMR analysis of the structure, dynamics, and unique oligomerization properties of the chemokine CCL27. J. Biol. Chem., 2010, 19(285), 14424-14437.
180. Kim, K. S.; Clark-Lewis, I.; Sykes, B. D. Solution structure of GRO/melanoma growth stimulatory activity determined by 1H NMR spectroscopy. J. Biol. Chem., 1994, 52(269), 32909-32915.
181. Fairbrother, W. J.; Reilly, D.; Colby, T. J.; Hesselgesser, J.; Horuk, R. The solution structure of melanoma growth stimulating activity. J. Mol. Biol., 1994, 3(242), 252-270.
182. Qian, Y. Q.; Johanson, K. O.; McDevitt, P. Nuclear magnetic resonance solution structure of truncated human grobeta [5-73] and its structural comparison with CXC chemokine family members groalpha and IL-8. J. Mol. Biol., 1999, 5(294), 1065-1072.
183. Rajasekaran, D.; Keeler, C.; Syed, M. A.; Jones, M. C.; Harrison, J. K.; Wu, D.; Bhandari, V.; Hodsdon, M. E.; Lolis, E. J. A model of GAG/MIP-2/CXCR2 interfaces and its functional effects. Biochemistry, 2012, 28(51), 5642-5654.
184. Zhang, X.; Chen, L.; Bancroft, D. P.; Lai, C. K.; Maione, T. E. Crystal structure of recombinant human platelet factor 4. Biochemistry, 1994, 27(33), 8361-8366.
185. Clore, G. M.; Appella, E.; Yamada, M.; Matsushima, K.; Gronenborn, A. M. Three-dimensional structure of interleukin 8 in solution. Biochemistry, 1990, 7(29), 1689-1696.
186. Baldwin, E. T.; Weber, I. T.; St Charles, R.; Xuan, J. C.; Appella, E.; Yamada, M.; Matsushima, K.; Edwards, B. F.; Clore, G. M.; Gronenborn, A. M. Crystal structure of interleukin 8: Symbiosis of NMR and crystallography. Proc. Natl. Acad. Sci. USA, 1991, 2(88), 502-506.
187. 1H NMR solution structure of an active monomeric interleukin-8. Biochemistry, 1995, 40(34), 12983-12990.
188. Booth, V.; Keizer, D. W.; Kamphuis, M. B.; Clark-Lewis, I.; Sykes, B. D. The CXCR3 binding chemokine IP-10/CXCL10: Structure and receptor interactions. Biochemistry, 2002, 33(41), 10418-10425.
189. Swaminathan, G. J.; Holloway, D. E.; Colvin, R. A.; Campanella, G. K.; Papageorgiou, A. C.; Luster, A. D.; Acharya, K. R. Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine. Structure, 2003, 5(11), 521-532.
190. Booth, V.; Clark-Lewis, I.; Sykes, B. D. NMR structure of CXCR3 binding chemokine CXCL11 (ITAC). Protein Sci., 2004, 8(13), 2022-2028.
191. Gozansky, E. K.; Louis, J. M.; Caffrey, M.; Clore, G. M. Mapping the binding of the n-terminal extracellular tail of the CXCR4 receptor to stromal cell-derived factor-1alpha. J. Mol. Biol., 2005, 4(345), 651-658.
192. Ryu, E. K.; Kim, T. G.; Kwon, T. H.; Jung, I. D.; Ryu, D.; Park, Y.-M.; Kim, J.; Ahn, K. H.; Ban, C. Crystal structure of recombinant human stromal cell-derived factor-1alpha. Proteins, 2007, 4(67), 1193-1197.
193. Murphy, J. W.; Yuan, H.; Kong, Y.; Xiong, Y.; Lolis, E. J. Heterologous quaternary structure of CXCL12 and its relationship to the CC chemokine family. Proteins, 2010, 5(78), 1331-1337.
194. Veldkamp, C. T.; Ziarek, J. J.; Su, J.; Basnet, H.; Lennertz, R.; Weiner, J. J.; Peterson, F. C.; Baker, J. E.; Volkman, B. F. Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12. Protein Sci., 2009, 7(18), 1359-1369.
195. Peterson, F. C.; Thorpe, J. A.; Harder, A. G.; Volkman, B. F.; Schwarze, S. R. Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26 S proteasome. J. Mol. Biol., 2006, 4(363), 813-822.
196. Kuloglu, E. S.; McCaslin, D. R.; Kitabwalla, M.; Pauza, C. D.; Markley, J. L.; Volkman, B. F. Monomeric solution structure of the prototypical 'C' chemokine lymphotactin. Biochemistry, 2001, 42(40), 12486-12496.
197. Tuinstra, R. L.; Peterson, F. C.; Elgin, E. S.; Pelzek, A. J.; Volkman, B. F. An engineered second disulfide bond restricts lymphotactin/XCL1 to a chemokine-like conformation with XCR1 agonist activity. Biochemistry, 2007, 10(46), 2564-2573.
198. Mizoue, L. S.; Bazan, J. F.; Johnson, E. C.; Handel, T. M. Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an n-terminal fragment of CX3CR1. Biochemistry, 1999, 5(38), 1402-1414.
199. Hoover, D. M.; Mizoue, L. S.; Handel, T. M.; Lubkowski, J. The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement. J. Biol. Chem., 2000, 30(275), 23187-23193.
200. Pakianathan, D. R.; Kuta, E. G.; Artis, D. R.; Skelton, N. J.; Hébert, C. A. Distinct but overlapping epitopes for the interaction of a ccchemokine with CCR1, CCR3 and CCR5. Biochemistry, 1997, 32(36), 9642-9648.
201. Proudfoot, A. E.; Power, C. A.; Hoogewerf, A. J.; Montjovent, M. O.; Borlat, F.; Offord, R. E.; Wells, T. N. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem., 1996, 5(271), 2599-2603.
202. Simmons, G.; Clapham, P. R.; Picard, L.; Offord, R. E.; Rosenkilde, M. M.; Schwartz, T. W.; Buser, R.; Wells, T. N.; Proudfoot, A. E. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 1997, 5310(276), 276-279.
203. Ye, J.; Kohli, L. L.; Stone, M. J. Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3. J. Biol. Chem., 2000, 35(275), 27250-27257.
204. Datta, A.; Stone, M. J. Soluble mimics of a chemokine receptor: Chemokine binding by receptor elements juxtaposed on a soluble scaffold. Protein Sci., 2003, 11(12), 2482-2491.
205. Wise, E. L.; Duchesnes, C.; Da Fonseca, P. C. A.; Allen, R. A.; Williams, T. J.; Pease, J. E. Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J. Biol. Chem., 2007, 38(282), 27935-27943.
206. Mayer, M. R.; Stone, M. J. Identification of receptor binding and activation determinants in the n-terminal and n-loop regions of the CC chemokine eotaxin. J. Biol. Chem., 2001, 17(276), 13911-13916.
207. Navenot, J. M.; Wang, Z. X.; Trent, J. O.; Murray, J. L.; Hu, Q. X.; De Leeuw, L.; Moore, P. S.; Chang, Y.; Peiper, S. C. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: Differences in primary structural requirements for RANTES, MIP-1 alpha, and vmip-ii binding. J. Mol. Biol., 2001, 5(313), 1181-1193.
208. Bondue, A.; Jao, S.-C.; Blanpain, C.; Parmentier, M.; Li Wang, P. J. Characterization of the role of the n-loop of MIP-1 beta in CCR5 binding. Biochemistry, 2002, 46(41), 13548-13555.
209. Laurence, J. S.; Blanpain, C.; De Leener, A.; Parmentier, M.; Li-Wang, P. J. Importance of basic residues and quaternary structure in the function of MIP-1 beta: CCR5 binding and cell surface sugar interactions. Biochemistry, 2001, 16(40), 4990-4999.
210. Kim, S.; Jao, S.; Laurence, J. S.; Li Wang, P. J. Structural comparison of monomeric variants of the chemokine mip-1beta having differing ability to bind the receptor CCR5. Biochemistry, 2001, 36(40), 10782-10791.
211. Laurence, J. S.; Blanpain, C.; Burgner, J. W.; Parmentier, M.; Li-Wang, P. J. CC chemokine MIP-1 beta can function as a monomer and depends on phe13 for receptor binding. Biochemistry, 2000, 12(39), 3401-3409.
212. Steen, A.; Thiele, S.; Guo, D.; Hansen, L. S.; Frimurer, T. M.; Rosenkilde, M. M. Biased and constitutive signaling in the ccchemokine receptor CCR5 by manipulating the interface between transmembrane helix 6 and 7. J. Biol. Chem., 2013, 288, 12511-12521
213. Ott, T. R.; Lio, F. M.; Olshefski, D.; Liu, X.-J.; Ling, N.; Struthers, R. S. The n-terminal domain of CCL21 reconstitutes high affinity binding, G protein activation, and chemotactic activity, to the cterminal domain of CCL19. Biochem. Biophys. Res. Commun., 2006, 3(348), 1089-1093.
214. Ott, T. R.; Lio, F. M.; Olshefski, D.; Liu, X.-J.; Struthers, R. S.; Ling, N. Determinants of high-affinity binding and receptor activation in the n-terminus of CCL-19 (MIP-3 beta). Biochemistry, 2004, 12(43), 3670-3678.
215. Ott, T. R.; Pahuja, A.; Nickolls, S. A.; Alleva, D. G.; Struthers, R. S. Identification of CC chemokine receptor 7 residues important for receptor activation. J. Biol. Chem., 2004, 41(279), 42383-42392.
216. Denis, C.; Deiteren, K.; Mortier, A.; Tounsi, A.; Fransen, E.; Proost, P.; Renauld, J.-C.; Lambeir, A.-M. C-terminal clipping of chemokine CCL1/I-309 enhances ccr8-mediated intracellular calcium release and anti-apoptotic activity. PLoS One., 2012, 3(7), e34199
217. Jensen, P. C.; Nygaard, R.; Thiele, S.; Elder, A.; Zhu, G.; Kolbeck, R.; Ghosh, S.; Schwartz, T. W.; Rosenkilde, M. M. Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8. Mol. Pharmacol., 2007, 2(72), 327-340.
218. Fox, J. M.; Najarro, P.; Smith, G. L.; Struyf, S.; Proost, P.; Pease, J. E. Structure/function relationships of CCR8 agonists and antagonists. Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist. J. Biol. Chem., 2006, 48(281), 36652-36661.
219. Rummel, P. C.; Arfelt, K. N.; Baumann, L.; Jenkins, T. J.; Thiele, S.; Lüttichau, H. R.; Johnsen, A.; Pease, J.; Ghosh, S.; Kolbeck, R.; Rosenkilde, M. M. Molecular requirements for inhibition of the chemokine receptor ccr8-probe-dependent allosteric interactions. Br. J. Pharmacol., 2012, 6(167), 1206-1217.
220. Joseph, P. R. B.; Sarmiento, J. M.; Mishra, A. K.; Das, S. T.; Garofalo, R. P.; Navarro, J.; Rajarathnam, K. Probing the role of CXC motif in chemokine CXCL8 for high affinity binding and activation of CXCR1 and CXCR2 receptors. J. Biol. Chem., 2010, 38(285), 29262-29269.
221. Clark-Lewis, I.; Dewald, B.; Loetscher, M.; Moser, B.; Baggiolini, M. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. J. Biol. Chem., 1994, 23(269), 16075-16081.
222. Hesselgesser, J.; Chitnis, C. E.; Miller, L. H.; Yansura, D. G.; Simmons, L. C.; Fairbrother, W. J.; Kotts, C.; Wirth, C.; Gillece-Castro, B. L.; Horuk, R. A mutant of melanoma growth stimulating activity does not activate neutrophils but blocks erythrocyte invasion by malaria. J. Biol. Chem., 1995, 19(270), 11472-11476.
223. Ahuja, S. K.; Lee, J. C.; Murphy, P. M. CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J. Biol. Chem., 1996, 1(271), 225-232.
224. Katancik, J. A.; Sharma, A.; De Nardin, E. Interleukin 8, neutrophilactivating peptide-2 and gro-alpha bind to and elicit cell activation via specific and different amino acid residues of CXCR2. Cytokine, 2000, 10(12), 1480-1488.
225. Gayle, R. B.; Sleath, P. R.; Srinivason, S.; Birks, C. W.; Weerawarna, K. S.; Cerretti, D. P.; Kozlosky, C. J.; Nelson, N.; Vanden Bos, T.; Beckmann, M. P. Importance of the amino terminus of the interleukin-8 receptor in ligand interactions. J. Biol. Chem., 1993, 10(268), 7283-7289.
226. De Kruijf, P.; Lim, H. D.; Roumen, L.; Renjaän, V. A.; Zhao, J.; Webb, M. L.; Auld, D. S.; Wijkmans, J. C. H. M.; Zaman, G. J. R.; Smit, M. J.; De Graaf, C.; Leurs, R. Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol. Pharmacol., 2011, 6(80), 1108-1118.
227. Clark-Lewis, I.; Mattioli, I.; Gong, J.-H.; Loetscher, P. Structurefunction relationship between the human chemokine receptor CXCR3 and its ligands. J. Biol. Chem., 2003, 1(278), 289-295.
228. Campanella, G. S. V.; Lee, E. M. J.; Sun, J.; Luster, A. D. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J. Biol. Chem., 2003, 19(278), 17066-17074.
229. Rosenkilde, M. M.; Andersen, M. B.; Nygaard, R.; Frimurer, T. M.; Schwartz, T. W. Activation of the CXCR3 chemokine receptor through anchoring of a small molecule chelator ligand between TM-III, -IV, and-VI. Mol. Pharmacol., 2007, 3(71), 930-941.
230. Rosenkilde, M. M.; Gerlach, L.-O.; Jakobsen, J. S.; Skerlj, R. T.; Bridger, G. J.; Schwartz, T. W. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: Transfer of binding site to the CXCR3 receptor. J. Biol. Chem., 2004, 4(279), 3033-3041.
231. Nedjai, B.; Li, H.; Stroke, I. L.; Wise, E. L.; Webb, M. L.; Merritt, J. R.; Henderson, I.; Klon, A. E.; Cole, A. G.; Horuk, R.; Vaidehi, N.; Pease, J. E. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Br. J. Pharmacol., 2012, 3(166), 912-923.
232. Xanthou, G.; Duchesnes, C. E.; Williams, T. J.; Pease, J. E. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur. J. Immunol., 2003, 8(33), 2241-2250.
233. Xanthou, G.; Williams, T. J.; Pease, J. E. Molecular characterization of the chemokine receptor CXCR3: Evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur. J. Immunol., 2003, 10(33), 2927-2936.
234. Ohnishi, Y.; Senda, T.; Nandhagopal, N.; Sugimoto, K.; Shioda, T.; Nagal, Y.; Mitsui, Y. Crystal structure of recombinant native sdf-1alpha with additional mutagenesis studies: An attempt at a more comprehensive interpretation of accumulated structure-activity relationship data. J. Interferon Cytokine Res., 2000, 8(20), 691-700.
235. Sundstrom, M.; White, R. L.; De Parseval, A.; Sastry, K. J.; Morris, G.; Grant, C. K.; Elder, J. H. Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein. J. Virol., 2008, 18(82), 9134-9142.
236. Wang, J.; Babcock, G. J.; Choe, H.; Farzan, M.; Sodroski, J.; Gabuzda, D. N-linked glycosylation in the CXCR4 n-terminus inhibits binding to HIV-1 envelope glycoproteins. Virology, 2004, 1(324), 140-150.
237. Huang, X.; Shen, J.; Cui, M.; Shen, L.; Luo, X.; Ling, K.; Pei, G.; Jiang, H.; Chen, K. Molecular dynamics simulations on sdf-1alpha: Binding with CXCR4 receptor. Biophys J., 2003, 1(84), 171-184.
238. Farzan, M.; Babcock, G. J.; Vasilieva, N.; Wright, P. L.; Kiprilov, E.; Mirzabekov, T.; Choe, H. The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1 entry. J. Biol. Chem., 2002, 33(277), 29484-29489.
239. Zhou, N.; Luo, Z.; Luo, J.; Liu, D.; Hall, J. W.; Pomerantz, R. J.; Huang, Z. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J. Biol. Chem., 2001, 46(276), 42826-42833.
240. Doranz, B. J.; Orsini, M. J.; Turner, J. D.; Hoffman, T. L.; Berson, J. F.; Hoxie, J. A.; Peiper, S. C.; Brass, L. F.; Doms, R. W. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J. Virol., 1999, 4(73), 2752-2761.
241. Tian, S.; Choi, W.-T.; Liu, D.; Pesavento, J.; Wang, Y.; An, J.; Sodroski, J. G.; Huang, Z. Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains. J. Virol., 2005, 20(79), 12667-12673.
242. Brelot, A.; Heveker, N.; Montes, M.; Alizon, M. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J. Biol. Chem., 2000, 31(275), 23736-23744.
243. Dong, C.-Z.; Kumar, S.; Choi, W.-T.; Madani, N.; Tian, S.; An, J.; Sodroski, J. G.; Huang, Z. Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an antihiv, d-amino acid-containing smm-chemokine ligand. J. Med. Chem., 2005, 25(48), 7923-7924.
244. Valenzuela-Fernández, A.; Planchenault, T.; Baleux, F.; Staropoli, I.; Le-Barillec, K.; Leduc, D.; Delaunay, T.; Lazarini, F.; Virelizier, J.-L.; Chignard, M.; Pidard, D.; Arenzana-Seisdedos, F. Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J. Biol. Chem., 2002, 18(277), 15677-15689.
245. Heveker, N.; Montes, M.; Germeroth, L.; Amara, A.; Trautmann, A.; Alizon, M.; Schneider-Mergener, J. Dissociation of the signalling and antiviral properties of sdf-1-derived small peptides. Curr. Biol., 1998, 7(8), 369-376.
246. Loetscher, P.; Gong, J. H.; Dewald, B.; Baggiolini, M.; Clark-Lewis, I. N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J. Biol. Chem., 1998, 35(273), 22279-22283.
247. Gupta, S. K.; Pillarisetti, K.; Thomas, R. A.; Aiyar, N. Pharmacological evidence for complex and multiple site interaction of CXCR4 with sdf-1alpha: Implications for development of selective CXCR4 antagonists. Immunol. Lett., 2001, 1(78), 29-34.
248. Rosenkilde, M. M.; Gerlach, L.-O.; Hatse, S.; Skerlj, R. T.; Schols, D.; Bridger, G. J.; Schwartz, T. W. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J. Biol. Chem., 2007, 37(282), 27354-27365.
249. Shimaoka, T.; Nakayama, T.; Hieshima, K.; Kume, N.; Fukumoto, N.; Minami, M.; Hayashida, K.; Kita, T.; Yoshie, O.; Yonehara, S. Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain. J. Biol. Chem., 2004, 26(279), 26807-26810.
250. McDermott, D. H.; Fong, A. M.; Yang, Q.; Sechler, J. M.; Cupples, L. A.; Merrell, M. N.; Wilson, P. W. F.; D'Agostino, R. B.; O'Donnell, C. J.; Patel, D. D.; Murphy, P. M. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest., 2003, 8(111), 1241-1250.
251. McDermott, D. H.; Halcox, J. P.; Schenke, W. H.; Waclawiw, M. A.; Merrell, M. N.; Epstein, N.; Quyyumi, A. A.; Murphy, P. M. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ. Res., 2001, 5(89), 401-407.
252. Faure, S.; Meyer, L.; Costagliola, D.; Vaneensberghe, C.; Genin, E.; Autran, B.; Delfraissy, J. F.; McDermott, D. H.; Murphy, P. M.; Debré, P.; Théodorou, I.; Combadière, C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science, 2000, 5461(287), 2274-2277.
253. Chen, Y.; Green, S. R.; Almazan, F.; Quehenberger, O. The amino terminus and the third extracellular loop of CX3CR1 contain determinants critical for distinct receptor functions. Mol. Pharmacol., 2006, 3(69), 857-865.
254. Harrison, J. K.; Fong, A. M.; Swain, P. A.; Chen, S.; Yu, Y. R.; Salafranca, M. N.; Greenleaf, W. B.; Imai, T.; Patel, D. D. Mutational analysis of the fractalkine chemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion. J. Biol. Chem., 2001, 24(276), 21632-21641.
255. Mizoue, L. S.; Sullivan, S. K.; King, D. S.; Kledal, T. N.; Schwartz, T. W.; Bacon, K. B.; Handel, T. M. Molecular determinants of receptor binding and signaling by the CX3C chemokine fractalkine. J. Biol. Chem., 2001, 36(276), 33906-33914.
256. Davis, C. N.; Zujovic, V.; Harrison, J. K. Viral macrophage inflammatory protein-ii and fractalkine (CX3CL1) chimeras identify molecular determinants of affinity, efficacy, and selectivity at CX3CR1. Mol. Pharmacol., 2004, 6(66), 1431-1439.
257. Marcaurelle, L. A.; Mizoue, L. S.; Wilken, J.; Oldham, L.; Kent, S. B.; Handel, T. M.; Bertozzi, C. R. Chemical synthesis of lymphotactin: A glycosylated chemokine with a c-terminal mucin-like domain. Chemistry, 2001, 5(7), 1129-1132.
258. Hedrick, J. A.; Saylor, V.; Figueroa, D.; Mizoue, L.; Xu, Y.; Menon, S.; Abrams, J.; Handel, T.; Zlotnik, A. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J. Immunol., 1997, 4(158), 1533-1540.
259. Dorner, B.; Müller, S.; Entschladen, F.; Schröder, J. M.; Franke, P.; Kraft, R.; Friedl, P.; Clark-Lewis, I.; Kroczek, R. A. Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8 (+) T cells. J. Biol. Chem., 1997, 13(272), 8817-8823.
260. Kennedy, J.; Kelner, G. S.; Kleyensteuber, S.; Schall, T. J.; Weiss, M. C.; Yssel, H.; Schneider, P. V.; Cocks, B. G.; Bacon, K. B.; Zlotnik, A. Molecular cloning and functional characterization of human lymphotactin. J. Immunol., 1995, 1(155), 203-209.
261. Kelner, G. S.; Kennedy, J.; Bacon, K. B.; Kleyensteuber, S.; Largaespada, D. A.; Jenkins, N. A.; Copeland, N. G.; Bazan, J. F.; Moore, K. W.; Schall, T. J. Lymphotactin: A cytokine that represents a new class of chemokine. Science, 1994, 5189(266), 1395-1399.